{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:51:55Z","timestamp":1780357915230,"version":"3.54.1"},"reference-count":167,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is rising in incidence globally. It is the sixth most common cancer and the third leading cause of cancer-related mortality worldwide. Infection with hepatitis B and\/or C virus is a significant risk factor for developing HCC. These viruses exert their carcinogenicity in both direct and indirect ways, including induction of immune exhaustion with prolonged antigen exposure. Therefore, the best therapeutic option for HCC is prevention, i.e., Hepatitis B vaccination and treatment of viral hepatitis. However, when HCC develops because of viral hepatitis or other etiologies, long-lasting effects on the immune system remain even after viral suppression, which affect the response to HCC therapy. Recent studies have suggested a \u201chot\u201d and \u201ccold\u201d model for HCC, in which the two kinds of HCC tumors have very distinct tumor microenvironments. The microenvironment for hot HCC makes these tumors amenable to immunotherapy with checkpoint inhibitors. Therefore, converting cold HCC tumors to hot tumors may make them susceptible to immunotherapy. In this review, we provide an overview of HCC epidemiology and prevention, an overview of tumor microenvironments of hot and cold HCC, the proposed mechanisms for converting cold tumors to hot tumors, and a concise summary of the evidence for combination checkpoint inhibitor therapy for HCC.<\/jats:p>","DOI":"10.3390\/v17091255","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T11:00:00Z","timestamp":1758106800000},"page":"1255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy"],"prefix":"10.3390","volume":"17","author":[{"given":"Laura","family":"Sneller","sequence":"first","affiliation":[{"name":"College of Medicine, Drexel University College of Medicine, 2900 W Queen Ln, Philadelphia, PA 19116, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav","family":"Mathur","sequence":"additional","affiliation":[{"name":"Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave NW, Washington, DC 20001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7471-0812","authenticated-orcid":false,"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, 725 W Lombard St., Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1346-9388","authenticated-orcid":false,"given":"Poonam","family":"Mathur","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, 725 W Lombard St., Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","unstructured":"Asafo-Agyei, K.O., and Samant, H. (2025). Hepatocellular Carcinoma. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/sjg.sjg_260_21","article-title":"Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma","volume":"28","author":"Chen","year":"2022","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pavlovi\u0107, N., and Heindryckx, F. (2021). Exploring the Role of Endoplasmic Reticulum Stress in Hepatocellular Carcinoma through mining of the Human Protein Atlas. Biology, 10.","DOI":"10.3390\/biology10070640"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2014.07.001","article-title":"ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development","volume":"26","author":"Nakagawa","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e154515","DOI":"10.1172\/JCI154515","article-title":"\u03b2-Catenin signaling in hepatocellular carcinoma","volume":"132","author":"Xu","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26868","DOI":"10.18632\/oncotarget.25525","article-title":"Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma","volume":"9","author":"Cassim","year":"2018","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","article-title":"Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma","volume":"39","author":"Feng","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, F., Wang, S., and Zhou, Q. (2020). The Resistance Mechanisms of Lung Cancer Immunotherapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.568059"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/hep.23173","article-title":"Chronically inflamed livers up-regulate expression of inhibitory B7 family members","volume":"50","author":"Kassel","year":"2009","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_15","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eaba6098","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2018.12.002","article-title":"Immune mechanisms mediating abscopal effects in radioimmunotherapy","volume":"196","author":"Rodriguez","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jama.2024.14101","article-title":"Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma","volume":"332","author":"Park","year":"2024","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.29971","article-title":"Population attributable fractions of risk factors for hepatocellular carcinoma in the United States","volume":"122","author":"Altekruse","year":"2016","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41575-023-00818-8","article-title":"Hepatocellular carcinoma surveillance\u2014utilization, barriers and the impact of changing aetiology","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jgh.14867","article-title":"The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis","volume":"35","author":"Tobari","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20420188231160389","DOI":"10.1177\/20420188231160389","article-title":"Should we undertake surveillance for HCC in patients with MAFLD?","volume":"14","author":"Norero","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: New trends","volume":"72","author":"Singal","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.cgh.2018.07.029","article-title":"Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance","volume":"17","author":"Simmons","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1478-3231.2004.00882.x","article-title":"Possible contribution of circulating transforming growth factor-\u03b21 to immunity and prognosis in unresectable hepatocellular carcinoma","volume":"24","author":"Okumoto","year":"2004","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cgh.2014.04.033","article-title":"Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder","volume":"13","author":"Beste","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.30129","article-title":"Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial","volume":"69","author":"Singal","year":"2019","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.188.2.341","article-title":"Immune Pathogenesis of Hepatocellular Carcinoma","volume":"188","author":"Nakamoto","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kouroumalis, E., Tsomidis, I., and Voumvouraki, A. (2023). Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041166"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0038-1676806","article-title":"Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets","volume":"39","author":"Yang","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hurtado-Navarro, L., Angosto-Bazarra, D., Pelegr\u00edn, P., Baroja-Mazo, A., and Cuevas, S. (2022). NLRP3 Inflammasome and Pyroptosis in Liver Pathophysiology: The Emerging Relevance of Nrf2 Inducers. Antioxidants, 11.","DOI":"10.3390\/antiox11050870"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Khare, S., Khare, T., Ramanathan, R., and Ibdah, J.A. (2022). Hepatocellular Carcinoma: The Role of MicroRNAs. Biomolecules, 12.","DOI":"10.3390\/biom12050645"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ruiz-Manriquez, L.M., Carrasco-Morales, O., Sanchez Z, E.A., Osorio-Perez, S.M., Estrada-Meza, C., Pathak, S., Banerjee, A., Bandyopadhyay, A., Duttaroy, A.K., and Paul, S. (2022). MicroRNA-mediated regulation of key signaling pathways in hepatocellular carcinoma: A mechanistic insight. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.910733"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hamaguchi, K., Miyanishi, K., Osuga, T., Tanaka, S., Ito, R., Sakamoto, H., Kubo, T., Ohnuma, H., Murase, K., and Takada, K. (2022). Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt\/\u03b2-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14092066"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/hep.29660","article-title":"Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies","volume":"67","author":"Simon","year":"2018","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kanda, T., Goto, T., Hirotsu, Y., Masuzaki, R., Moriyama, M., and Omata, M. (2020). Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041525"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., and Sasso, F.C. (2023). Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020468"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sasaki-Tanaka, R., Ray, R., Moriyama, M., Ray, R.B., and Kanda, T. (2022). Molecular Changes in Relation to Alcohol Consumption and Hepatocellular Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179679"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00432-003-0439-5","article-title":"Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma","volume":"129","author":"Munaka","year":"2003","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ijc.21505","article-title":"Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population","volume":"118","author":"Sakamoto","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ajg.2015.137","article-title":"PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease","volume":"110","author":"Salameh","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_48","first-page":"300","article-title":"Endotoxin and Kupffer cell activation in alcoholic liver disease","volume":"27","author":"Wheeler","year":"2003","journal-title":"Alcohol. Res. Health"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zheng, M., and Tian, Z. (2019). Liver-Mediated Adaptive Immune Tolerance. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02525"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s40425-019-0749-z","article-title":"Immunotherapy in hepatocellular carcinoma: The complex interface between inflammation, fibrosis, and the immune response","volume":"7","author":"Keenan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/hep.27793","article-title":"Liver inflammation abrogates immunological tolerance induced by Kupffer cells","volume":"62","author":"Heymann","year":"2015","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2019.08.014","article-title":"The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications","volume":"72","author":"Hou","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1158\/0008-5472.CAN-09-0901","article-title":"Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1\/Programmed Death-1 Interactions","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jhep.2013.04.033","article-title":"Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion","volume":"59","author":"Schildberg","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/onc.2016.273","article-title":"Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Massalha, H., Bahar Halpern, K., Abu-Gazala, S., Jana, T., Massasa, E.E., Moor, A.E., Buchauer, L., Rozenberg, M., Pikarsky, E., and Amit, I. (2020). A single cell atlas of the human liver tumor microenvironment. Mol. Syst. Biol., 16.","DOI":"10.15252\/msb.20209682"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e954829","DOI":"10.4161\/21624011.2014.954829","article-title":"Myeloid derived suppressor cells\u2014An overview of combat strategies to increase immunotherapy efficacy","volume":"4","author":"Draghiciu","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/labinvest.3700540","article-title":"Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells","volume":"87","author":"Cao","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chen, K.-J., Lin, S.-Z., Zhou, L., Xie, H.-Y., Zhou, W.-H., Taki-Eldin, A., and Zheng, S.-S. (2011). Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024671"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/bjc.2016.47","article-title":"Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection","volume":"114","author":"Fu","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000342801","article-title":"Tumor-Infiltrating FoxP3+ Tregs and CD8+ T Cells Affect the Prognosis of Hepatocellular Carcinoma Patients","volume":"86","author":"Huang","year":"2012","journal-title":"Digestion"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15129","DOI":"10.1038\/ncomms15129","article-title":"The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion","volume":"8","author":"Jiang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/jso.23227","article-title":"Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal","volume":"107","author":"Wang","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-Associated Macrophages: From Mechanisms to Therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2014.10.029","article-title":"Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma","volume":"62","author":"Yeung","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/ijc.24556","article-title":"Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients","volume":"125","author":"Zhou","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.26694","article-title":"Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma","volume":"59","author":"Han","year":"2014","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti\u2013PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"Bresnahan","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101213","DOI":"10.1016\/j.jceh.2023.06.013","article-title":"NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance","volume":"14","author":"Koh","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","article-title":"Translation control of the immune checkpoint in cancer and its therapeutic targeting","volume":"25","author":"Xu","year":"2019","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000451016","article-title":"Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials","volume":"92","author":"Kudo","year":"2017","journal-title":"Oncology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e5749","DOI":"10.1097\/MD.0000000000005749","article-title":"Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/tan.12278","article-title":"Tim-3 expression on peripheral monocytes and CD3+CD16\/CD56+natural killer-like T cells in patients with chronic hepatitis B","volume":"83","author":"Rong","year":"2014","journal-title":"Tissue Antigens"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease","volume":"168","author":"Shah","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1158\/1078-0432.CCR-17-0950","article-title":"Characterization of the Immune Microenvironment in Hepatocellular Carcinoma","volume":"23","author":"Yarchoan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1158\/1078-0432.CCR-14-1954","article-title":"High Serum Transforming Growth Factor-\u03b21 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib","volume":"21","author":"Lin","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/00000658-200004000-00015","article-title":"Serum Interleukin-10 But Not Interleukin-6 Is Related to Clinical Outcome in Patients With Resectable Hepatocellular Carcinoma","volume":"231","author":"Chau","year":"2000","journal-title":"Ann. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbrc.2015.03.177","article-title":"Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma","volume":"461","author":"Shi","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_85","first-page":"e85974","article-title":"TGF-\u03b2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies","volume":"1","author":"Courau","year":"2016","journal-title":"Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","author":"Das","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1189\/jlb.4RI0214-126R","article-title":"Immune control and failure in HCV infection\u2014Tipping the balance","volume":"96","author":"Dustin","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, S., Wang, L., and Ma, K. (2024). Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment. Biochim. Biophys. Acta Mol. Basis Dis., 1870.","DOI":"10.1016\/j.bbadis.2024.167230"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"106810","DOI":"10.4254\/wjh.v17.i7.106810","article-title":"Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management","volume":"17","author":"Pamungkas","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ren, S., Zhang, Y., Wang, X., Su, J., Wang, X., Yuan, Z., He, X., Guo, S., Chen, Y., and Deng, S. (2025). Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1526967"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e004779","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1002\/mco2.343","article-title":"Hot and cold tumors: Immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"Medcomm"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e150846","DOI":"10.1172\/JCI150846","article-title":"Targeting HIF-1alpha abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues","volume":"132","author":"Bailey","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4254\/wjh.v5.i6.302","article-title":"Management of hepatocellular carcinoma: Enlightening the gray zones","volume":"5","author":"Mancuso","year":"2013","journal-title":"World J. Hepatol."},{"key":"ref_100","first-page":"16","article-title":"Updates in the management of hepatocellular carcinoma","volume":"7","author":"Wong","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.3748\/wjg.v20.i12.3087","article-title":"Systemic therapy of hepatocellular carcinoma: Current status and future perspectives","volume":"20","author":"Germano","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma","volume":"304","author":"Johnson","year":"2010","journal-title":"JAMA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W.P., Chen, X., Wang, L., and Goh, B.C. (2023). Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: Factors, strategies, and ongoing trials. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1261575"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","article-title":"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): A randomised, open-label, phase 1b-2, study","volume":"26","author":"Finn","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"OncoImmunology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation","volume":"112","author":"Du","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4254\/wjh.v7.i3.362","article-title":"Diagnosis and treatment of hepatocellular carcinoma: An update","volume":"7","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molmed.2008.02.002","article-title":"Immunogenicity of anthracyclines: Moving towards more personalized medicine","volume":"14","author":"Apetoh","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1158\/0008-5472.CAN-16-0881","article-title":"Tumor Eradication by Cisplatin Is Sustained by CD80\/86-Mediated Costimulation of CD8+ T Cells","volume":"76","author":"Yagita","year":"2016","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Serpico, A.F., Pisauro, C., and Grieco, D. (2023). cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1127623"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3892\/mmr.2015.4171","article-title":"Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma","volume":"12","author":"Liao","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Cerullo","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRP\u03b1-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRP\u03b1 signal pathway via blocking the \u201cdon\u2019t eat me\u201d signal and activating the \u201ceat me\u201d signal","volume":"15","author":"Yu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Cueto, F.J., and Sancho, D. (2021). The Flt3L\/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13071525"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.21560","article-title":"Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors","volume":"45","author":"Chang","year":"2007","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hep.22296","article-title":"CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo\u2020","volume":"48","author":"Timmerman","year":"2008","journal-title":"Hepatology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/JHC.S301375","article-title":"The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma","volume":"8","author":"Zhou","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-20-4245","article-title":"Intravital Imaging Identifies the VEGF\u2013TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion","volume":"81","author":"Konishi","year":"2021","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Kudo, M. (2020). Scientific Rationale for Combined Immunotherapy with PD-1\/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12051089"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2017.09.006","article-title":"Migrating into the Tumor: A Roadmap for T Cells","volume":"3","author":"Gorris","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41467-018-03730-x","article-title":"Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers","volume":"9","author":"McGrail","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-021-24386-0","article-title":"Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11684-019-0684-x","article-title":"Adoptive cell transfer therapy for hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2019","journal-title":"Front. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2017.07.002","article-title":"T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC","volume":"6","author":"Szoor","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e003441","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/2326-6066.CIR-19-0210","article-title":"XCL1\/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti\u2013PD-1 Efficacy","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2021.09.028","article-title":"A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine","volume":"522","author":"Shi","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgh.15398","article-title":"Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma","volume":"36","author":"Teng","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e2105631","DOI":"10.1002\/advs.202105631","article-title":"Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency","volume":"9","author":"Wang","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-022-02307-3","article-title":"Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade","volume":"41","author":"Bai","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2486519","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: Immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., and Cui, X. (2025). Microbiome meets immunotherapy: Unlocking the hidden predictors of immune checkpoint inhibitors. NPJ Biofilms Microbiomes, 11.","DOI":"10.1038\/s41522-025-00819-2"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: From molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00432-020-03331-6","article-title":"Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma","volume":"146","author":"Zheng","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"101270","DOI":"10.1016\/j.jhepr.2024.101270","article-title":"AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection","volume":"7","author":"Chen","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/JHC.S450468","article-title":"CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils","volume":"11","author":"Wang","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00432-006-0075-y","article-title":"Dendritic cell infiltration and prognosis of human hepatocellular carcinoma","volume":"132","author":"Cai","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"39658","DOI":"10.18632\/oncotarget.17340","article-title":"Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: A meta-analysis","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.31165","article-title":"Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma","volume":"73","author":"Ahn","year":"2021","journal-title":"Hepatology"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Zhang, N., Yang, X., Piao, M., Xun, Z., Wang, Y., Ning, C., Zhang, X., Zhang, L., Wang, Y., and Wang, S. (2024). Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark. Res., 12.","DOI":"10.1186\/s40364-023-00535-z"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.3748\/wjg.v28.i36.5250","article-title":"Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma","volume":"28","author":"Devan","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.21037\/tcr-21-127","article-title":"Functions of CXC chemokines as biomarkers and potential therapeutic targets in the hepatocellular carcinoma microenvironment","volume":"10","author":"Wang","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"133","author":"Lee","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Wang, G., Zhang, W., Luan, X., Wang, Z., Liu, J., Xu, X., Zhang, J., Xu, B., Lu, S., and Wang, R. (2023). The role of (18)F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1151967"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing Genome-Driven Oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:01Z","timestamp":1760035621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":167,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["v17091255"],"URL":"https:\/\/doi.org\/10.3390\/v17091255","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}